Search
PARP inhibitor
Indications:
- PARP inhibitors are FDA-approved to treat androgen-independent metastatic prostate cancer
- olaparib (Lynparza) is a poly ADP-ribose polymerase inhibitor FDA-approved to treat advanced ovarian cancer with germline BRCA mutations
- niraparib (Zejula) is a poly ADP-ribose polymerase inhibitor FDA-approved for maintenance treatment of recurrent epithelial cancers (ovarian cancer, fallopian tube cancer, primary peritoneal cancer)
Mechanism of action:
- inhibitors of poly-ADP-ribose polymerase (PARP)
- current PARP inhibitors are also small inhibitory antineoplastic agents
Related
NAD+ ADP-ribosyltransferase or poly ADP-ribose polymerase
Specific
iniparib
niraparib (Zejula)
olaparib (Lynparza)
rucaparib (Rubraca)
talazoparib (Talzenna)
General
enzyme inhibitor
References
- Mittal K
Genomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer -
Prospective evidence supporting use of fresh biopsies rather than
archival specimens for genomic profiling.
MedPage Todau. ASCO Reading Room 12.02.2020
https://www.medpagetoday.com/reading-room/asco/non-prostate-genitourinary-cancer/89958
- Gilson C, et al
Genomic profiles of de novo high- and low-volume metastatic prostate cancer:
Results from a 2-stage feasibility and prevalence study in the STAMPEDE trial/.
JCO Precis Oncol 2020; 4: 882-897
Not indexed in PubMed
https://ascopubs.org/doi/full/10.1200/PO.19.00388%C2%A0